| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2021. Refer to TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis for full guidance on NICE recommendations, including any restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|
Medicine details |
|
| Medicine name | budesonide (Jorveza®) |
| Formulation | 1 mg orodispersible tablet |
| Reference number | 2656 |
| Indication | Treatment of eosinophilic oesophagitis in adults (older than 18 years of age). |
| Company | Dr Falk Pharma UK Ltd |
| BNF chapter | Gastro-intestinal system |
| Submission type | Non-submission |
| Status | Superseded |
| Date of issue | 20/04/2018 |
| NICE guidance | TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis |